최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0942482 (2013-07-15) |
등록번호 | US-9241903 (2016-01-26) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 1 인용 특허 : 802 |
Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperaz
Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
1. A dry powder medicament with an improved pharmaceutic property, made by a process comprising a) forming microparticles comprising a diketopiperazine by adjusting the pH of a solution comprising a diketopiperazine having acidic or basic side chains, resulting in a suspension of microparticles of t
1. A dry powder medicament with an improved pharmaceutic property, made by a process comprising a) forming microparticles comprising a diketopiperazine by adjusting the pH of a solution comprising a diketopiperazine having acidic or basic side chains, resulting in a suspension of microparticles of the diketopiperazine with acidic or basic side chains in a solvent, and optionally loading said microparticles with an active agent, thenb) removing solvent by spray drying to obtain a dry powder, wherein the dry powder has an improved pharmaceutic property as compared to a dry powder obtained by removing solvent by lyophilization, and wherein the improved pharmaceutic property is increased density of the powder, increased aerodynamic performance of the powder, or improved stability of the active agent, if present. 2. The dry powder of claim 1, wherein said diketopiperazine is a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is succinyl, glutaryl, maleyl, or fumaryl. 3. The dry powder of claim 2, wherein the diketopiperazine is fumaryl diketopiperazine. 4. The dry powder of claim 1, wherein the process comprises loading the microparticle with an active agent prior to the solvent removal step. 5. The dry powder of claim 4, wherein said loading step comprises: providing a solution or a suspension of the active agent; and adding said solution or suspension of active agent to the suspension of microparticles of the diketopiperazine with acidic or basic side chains. 6. The dry powder of claim 4, wherein the active agent is insulin, calcitonin, parathyroid hormone 1-34, bioactive fragment of parathyroid hormone, octreotide, leuprolide, RSV peptide, felbamate, cannabinoid antagonists and/or agonists, muscurinic antagon and/or agonists, heparin, low molecular weight heparin, cromolyn, sildenafil, vardenafil, tadalafil, growth hormone, AZT, DDI, GCSF, lamotrigine, chorionic gonadotropin releasing factor, luteinizing release hormone, βgalactosidase, GLP-1, exendins 1-4, or ghrelin. 7. The dry powder of claim 4, wherein the active agent is a peptide or protein. 8. The dry powder of claim 6, wherein the active agent is insulin or an analogue thereof. 9. The dry powder of claim 1, wherein said improved pharmaceutic property is improved aerodynamic performance of the microparticle. 10. The dry powder of claim 1, wherein said improved pharmaceutic property is increased density of the powder. 11. The dry powder of claim 4, wherein said improved pharmaceutic property is improved stability of the active agent of the microparticle. 12. The dry powder of claim 9, wherein said aerodynamic performance is measured by the percent respirable fraction on a cartridge fill. 13. The dry powder of claim 12, wherein the percent respirable fraction is greater than about 40%. 14. The dry powder of claim 12, wherein the percent respirable fraction is greater than about 50%. 15. The dry powder of claim 12, wherein the percent respirable fraction is greater than about 60%. 16. The dry powder of claim 8, wherein the insulin content of the microparticle is about 3% to about 50% by weight of the dry powder formulation. 17. The dry powder of claim 16, wherein the insulin content of the microparticle is about 7% to about 25% by weight of the dry powder formulation. 18. The dry powder of claim 17, wherein the insulin content of the microparticle is about 11% by weight of the dry powder formulation. 19. A method for delivering an active agent to a patient in need thereof, comprising administering by inhalation to the patient an effective amount of the dry powder of claim 4. 20. The dry powder of claim 10, wherein said increased density is 1.7 to 2.3 times the density of said dry powder obtained by removing solvent by lyophilization. 21. The dry powder of claim 20, wherein said increased density comprises greater tapped density. 22. The dry powder of claim 20, wherein said increased density comprises greater bulk density. 23. The dry powder of claim 21, wherein said greater tapped density is from 0.25 to 0.30 g/cc. 24. The dry powder of claim 22, wherein said greater bulk density is from 0.15 to 0.20 g/cc.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.